Atjaunināt sīkdatņu piekrišanu

Molecular Pathway Analysis Using High-Throughput OMICS Molecular Data: Analysis of molecular pathway composition, architecture, and activation using high-throughput genomic, epigenetic, transcriptomic, proteomic, and metabolomic data [Mīkstie vāki]

Edited by (Sechenov First Moscow Medical University, Moscow Institute of Physics and Technology, and Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russian Federation, Oncobox, Moscow, Russian Federation; Omicsway Corp., Walnut, C)
  • Formāts: Paperback / softback, 408 pages, height x width: 235x191 mm, weight: 830 g
  • Izdošanas datums: 29-Oct-2024
  • Izdevniecība: Academic Press Inc
  • ISBN-10: 0443155682
  • ISBN-13: 9780443155680
Citas grāmatas par šo tēmu:
  • Mīkstie vāki
  • Cena: 166,55 €
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
  • Formāts: Paperback / softback, 408 pages, height x width: 235x191 mm, weight: 830 g
  • Izdošanas datums: 29-Oct-2024
  • Izdevniecība: Academic Press Inc
  • ISBN-10: 0443155682
  • ISBN-13: 9780443155680
Citas grāmatas par šo tēmu:

The field molecular pathway analysis evolves rapidly, and many progressive methods have recently been discovered. Molecular Pathway Analysis Using High-Throughput OMICS Data contains the largest collections of molecular pathways. For the first time, guidelines on how to do genomic, epigenetic, transcriptomic, proteomic, and metabolomic data analysis in real-world research practice are given. Molecular Pathway Analysis Using High-Throughput OMICS Molecular Data also focuses on the pathway analysis applications for solving tasks in biotechnology, pharmaceutics, and molecular diagnostics ??It demonstrates how pathway analysis can be applied for the research and treatment of chronic and acute diseases, for next-generation molecular diagnostics, for drug design and preclinical testing; relevant real-world examples, molecular tests, and web resources will be reviewed in-depth.? ??The book shows a tendency of erasing the borders between chemistry, physics, informatics, mathematics, biology, and medicine by means of novel research approaches and instruments, providing a truly multidisciplinary approach.

1. Past, current, and future of molecular pathway analysis
2. Molecular data for the pathway analysis
3. Benefits and challenges of OMICS data integration at the pathway level
4. Controls for the molecular data: normalization, harmonization, and quality thresholds
5. Reconstruction of molecular pathways
6. Qualitative and quantitative molecular pathway analysis: mathematical methods and algorithms Methods and guidelines
7. Getting started with the molecular pathway analysis
8. Differential analysis of genes, proteins, and metabolites
9. Molecular pathway analysis using comparative genomic and epigenomic
10. Quantitative molecular pathway analysis using transcriptomic data
11. Proteomic data for quantitative molecular pathway analysis
12. Metabolomic data for quantitative molecular pathway analysis
13. Methods and tools for OMICS data integration Practical applications
14. Molecular pathway approach in medicine
15. Molecular pathway approach in pharmaceutics
16. Molecular pathway approach in biotechnology
17. Molecular pathway approach in life science studies
Anton Buzdin is professor and head of laboratories at Sechenov First Moscow Medical University, Moscow Institute of Physics and Technology, and Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry. He was elected as the chair of Biostatistics and Bioinformatics subgroup, Pathobiology Group of European Organization for Research and Treatment of Cancer (EORTC). Professor Buzdin is cofounder and chief scientific officer of Oncobox, which is a translational oncology company. He has authored more than 170 scientific papers and patent applications, and has worked as chief executive of several biotechnological and biomedical companies in Russia, Hong Kong and in the United States. He has also chaired two clinical trials of transcriptomics-based diagnostic tools in oncology. Professor Buzdins team pioneered bioinformatic quantitative analysis of molecular pathways using gene expression data and developed specialized algorithms and software packages to personalize prescription of targeted immunotherapy and chemotherapy drugs to cancer patients that were clinically validated and commercialized.